Compare BLKB & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLKB | DRTS |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2004 | 2021 |
| Metric | BLKB | DRTS |
|---|---|---|
| Price | $49.04 | $11.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $56.25 | $20.60 |
| AVG Volume (30 Days) | 362.5K | ★ 534.2K |
| Earning Date | 10-28-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.32 | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.30 | N/A |
| Revenue Next Year | $4.68 | $2,043.98 |
| P/E Ratio | $20.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.58 | $3.43 |
| 52 Week High | $64.84 | $15.79 |
| Indicator | BLKB | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 38.59 | 32.73 |
| Support Level | $45.72 | $6.68 |
| Resistance Level | $50.76 | $11.48 |
| Average True Range (ATR) | 1.71 | 0.83 |
| MACD | -0.88 | -0.20 |
| Stochastic Oscillator | 0.00 | 8.38 |
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.